MRO Tracker · Pharma
A free public sample tracking new API, starting material, peptide and CDMO plants in India, with capacity, investment, build stage and an analyst note for each project. Need a full map of a molecule or segment? Ask us for a custom study.
12projects
6states
9commissioned
14 Nov 2026last reviewed
Penicillin G fermentation plant
- Capacity
- 15,000 MT a year of Penicillin G; 1,80,000 MT of glucose
- Investment
- Rs 2,270.05 crore
- Commissioning
- Commissioned April 2024 under the bulk drugs PLI scheme
- End use
- Penicillin based antibiotics
- Stage
- Commissioned
MRO View: India's largest bet on fermentation based antibiotic inputs. The plant has created 2,353 direct jobs and logged cumulative production of Rs 1,191 crore so far.
6 APA plant
- Capacity
- 3,600 MT a year
- Investment
- Not disclosed
- Commissioning
- Commissioned April 2024
- End use
- Semi synthetic penicillins
- Stage
- Commissioned
MRO View: Sits next to the Penicillin G plant, so Aurobindo now makes the antibiotic chain from fermentation to intermediate in one SEZ.
Potassium clavulanate plant
- Capacity
- 400 MT a year
- Investment
- Rs 504.68 crore
- Commissioning
- Commissioned under the bulk drugs PLI scheme
- End use
- Amoxicillin clavulanate combinations
- Stage
- Commissioned
MRO View: India's first fermentation based clavulanate plant. Domestic demand was put at about 700 tonnes a year when the project began, so imports still fill part of the gap.
Sulfadiazine, Telmisartan and Olmesartan API plant
- Capacity
- Not disclosed
- Investment
- Rs 151.47 crore
- Commissioning
- Commissioned under the bulk drugs PLI scheme
- End use
- Anti infective and cardiovascular medicines
- Stage
- Commissioned
MRO View: Adds domestic supply of two widely used blood pressure APIs and creates 221 direct jobs.
Para amino phenol plant
- Capacity
- 13,500 MT a year
- Investment
- Rs 60.46 crore
- Commissioning
- Commissioned under the bulk drugs PLI scheme
- End use
- Paracetamol
- Stage
- Commissioned
MRO View: Built for about Rs 60 crore, the plant has already logged cumulative production of Rs 687 crore of the main paracetamol starting material, which was earlier largely imported.
Atorvastatin API plant
- Capacity
- 206 MT a year
- Investment
- Rs 161.13 crore
- Commissioning
- Commissioned under the bulk drugs PLI scheme
- End use
- Cholesterol lowering medicines
- Stage
- Commissioned
MRO View: Cumulative production has reached Rs 432 crore, ahead of the plant's capital cost.
Unit III greenfield plant, Phase 1
- Capacity
- Not disclosed
- Investment
- Not disclosed
- Commissioning
- Commercial operations from 1 Jan 2025
- End use
- Key starting materials and intermediates for its API and custom synthesis business
- Stage
- Commissioned
MRO View: Divi's is using Unit III for pre chemistry work to free GMP space at its older units, and plans to qualify it for regulated manufacturing over time.
Commercial peptide plant, Module 1
- Capacity
- 7,000 L reactor capacity (750 L solid phase, 6,250 L liquid phase)
- Investment
- USD 30 million
- Commissioning
- Operations began September 2026
- End use
- Peptide APIs for innovator and biotech clients, including GLP 1 programmes
- Stage
- Commissioned
MRO View: The first of four modules. Module 2 is planned at up to 18,000 L and will be sized to an anchor customer's needs.
Commercial fermentation plant, Phase 1
- Capacity
- More than 400 kL
- Investment
- USD 40 million for Phase 1 construction
- Commissioning
- Operational by end 2026 (company)
- End use
- Microbial fermentation for CDMO clients
- Stage
- Under construction
MRO View: A step into large scale biomanufacturing for a company best known for chemistry. It sits alongside new ADC and gene therapy capacity Laurus is building in Hyderabad.
Laurus Pharma Zone campus
- Capacity
- Not disclosed; 531.77 acres allotted
- Investment
- More than USD 600 million over eight years (company)
- Commissioning
- Capex to begin toward the end of FY27
- End use
- APIs, CDMO and formulations
- Stage
- Approved
MRO View: One of the largest single pharma land allotments in Andhra Pradesh. Spending starts late FY27, so output is a FY29 or later story.
Greenfield excipients and specialty ingredients plant
- Capacity
- 51,200 MT a year
- Investment
- Not disclosed
- Commissioning
- State FDA approval to begin manufacturing disclosed 26 Oct 2026; supplies from H2 FY27
- End use
- Pharma excipients and food and nutrition ingredients
- Stage
- Approved
MRO View: About 60% of capacity is earmarked for the company's existing pharma and nutrition portfolio, which lowers ramp up risk once customer qualification is done.
Additional xanthine derivatives block
- Capacity
- Not disclosed
- Investment
- Not disclosed
- Commissioning
- Inaugurated June 2026; trial production started
- End use
- Caffeine and other xanthine derivatives
- Stage
- Commissioned
MRO View: The company says the block places it among the top three xanthine derivative makers globally, with ramp up planned over the next few quarters.
All 12 projects at a glance
| Company | Project | State | Capacity | Stage |
|---|---|---|---|---|
| Lyfius Pharma (Aurobindo Pharma) | Penicillin G fermentation plant | Andhra Pradesh | 15,000 MT a year of Penicillin G; 1,80,000 MT of glucose | Commissioned |
| Qule Pharma (Aurobindo Pharma) | 6 APA plant | Andhra Pradesh | 3,600 MT a year | Commissioned |
| Kinvan Pvt Ltd (DPB Group) | Potassium clavulanate plant | Himachal Pradesh | 400 MT a year | Commissioned |
| Andhra Organics (Virchow Laboratories) | Sulfadiazine, Telmisartan and Olmesartan API plant | Andhra Pradesh | Not disclosed | Commissioned |
| Meghmani LLP | Para amino phenol plant | Gujarat | 13,500 MT a year | Commissioned |
| Centrient Pharmaceuticals India | Atorvastatin API plant | Punjab | 206 MT a year | Commissioned |
| Divi's Laboratories | Unit III greenfield plant, Phase 1 | Andhra Pradesh | Not disclosed | Commissioned |
| Neuland Laboratories | Commercial peptide plant, Module 1 | Telangana | 7,000 L reactor capacity (750 L solid phase, 6,250 L liquid phase) | Commissioned |
| Laurus Bio (Laurus Labs) | Commercial fermentation plant, Phase 1 | Andhra Pradesh | More than 400 kL | Under construction |
| Laurus Labs | Laurus Pharma Zone campus | Andhra Pradesh | Not disclosed; 531.77 acres allotted | Approved |
| Sudeep Pharma | Greenfield excipients and specialty ingredients plant | Gujarat | 51,200 MT a year | Approved |
| Aarti Pharmalabs | Additional xanthine derivatives block | Maharashtra | Not disclosed | Commissioned |
Need the numbers behind this tracker?
We map API capacity, import dependence and plant pipelines for pharma clients.
Get the monthly India tracker updateNew state data and new plant announcements in one short email, once a month.
One email a month. Reply to any email to unsubscribe. Privacy policy